Nanobiotix Reveals Enhanced Bioavailability and Reduced Toxicity in Preclinical Study

Nanobiotix has unveiled promising preclinical data suggesting improved systemic bioavailability and lower toxicity for DNA immunotherapy delivered via lipid nanoparticles (LNPs) when pre-treated with its Nanoprimer technology. This study, conducted on mice, was presented at the 2026 Annual Meeting of the American Association for Cancer Research.

The research assessed Nanoprimer's ability to address rapid liver clearance, a common challenge for LNP therapies. Mice pre-treated with Nanoprimer showed higher systemic bioavailability, lower hepatic toxicity, and reduced inflammation related to the cGAS-STING pathway, compared to treatments without Nanoprimer.

The results indicate that Nanoprimer can enhance the delivery and efficacy of LNP-DNA therapies, potentially offering wider applications across different LNP designs. The company aims to further explore Nanoprimer's capabilities, both in collaboration with partners and through its internal pipeline.